Astrazeneca Pharma India and Sun Pharmaceutical Industries announced a second brand partnership for Sodium Zirconium Cyclosilicate (SZC) in India. This exclusive agreement is aimed at further accelerating availability of SZC, an innovative and highly effective treatment for Hyperkalaemia to more patients across India. Under the agreement, both companies will promote, market & distribute SZC in India under different brand names; AstraZeneca will market SZC as Lokelma� whereas Sun Pharma will promote and distribute the therapy as Gimliand�. AstraZeneca will retain the intellectual property rights to SZC and hold the Marketing Authorisation along with the import license of the molecule.Powered by Capital Market - Live News

AstraZeneca Pharma India announced the resignation of Manasa. R as company secretary with effect from 28 November 2025. Powered by Capital Market - Live News

Net profit of Astrazeneca Pharma India rose 41.09% to Rs 54.22 crore in the quarter ended September 2025 as against Rs 38.43 crore during the previous quarter ended September 2024. Sales rose 37.03% to Rs 559.09 crore in the quarter ended September 2025 as against Rs 408.00 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales559.09408.00 37 OPM %13.4512.88 - PBDT80.6860.35 34 PBT78.1151.03 53 NP54.2238.43 41 Powered by Capital Market - Live News

Astrazeneca Pharma India will hold a meeting of the Board of Directors of the Company on 7 November 2025.Powered by Capital Market - Live News

AstraZeneca Pharma India announced the resignation of Pankaj Jain as Head - Legal of the company with effect from 31 October 2025. Powered by Capital Market - Live News